DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 203858/S-002

SUPPLEMENT APPROVAL

Aegerion Pharmaceuticals
Attention: Martha Carter
Chief Regulatory Officer and Senior Vice President
101 Main Street, Suite 1850
Cambridge, MA 02142

Dear Ms. Carter:

Please refer to your Supplemental New Drug Application (sNDA) dated April 9, 2013, received April 9, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for JUXTAPID (lomitapide) Capsules.

This "Prior Approval" supplemental new drug application provides for revisions to the package insert in response to our letter dated February 12, 2013. Specifically, the following modifications have been made:

1. Addition of the following statement to the WARNINGS AND PRECAUTIONS section, 5.1 Risk of Hepatotoxicity subsection (Hepatic Steatosis):

   "JUXTAPID has not been studied concomitantly with other LDL-lowering agents that can also increase hepatic fat. Therefore, the combined use of such agents is not recommended."

2. Revision to Table 6 (Effect of Lomitapide on the Systemic Exposure of Coadministered Drugs) as follows:
   -Under "No dosing adjustments required for the following:", the dosing of coadministered drugs [Atorvastatin, Rosuvastatin, Fenofibrate (micronized), Ezetimibe, and Extended release niacin] was further defined as SINGLE DOSE.
   -Under the header "COADMINISTERED DRUG", the drugs Ethinyl estradiol and Norgestimate were added.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Eric Colman, MD
Deputy Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC C COLMAN
04/10/2013